|国家预印本平台
首页|linical study on Transcranial magnetoelectric encephalopathy treatment instrument treatmenting parkinson’s disease

linical study on Transcranial magnetoelectric encephalopathy treatment instrument treatmenting parkinson’s disease

linical study on Transcranial magnetoelectric encephalopathy treatment instrument treatmenting parkinson’s disease

中文摘要英文摘要

Objective] Evaluate on the treatment efficacy and safety for transcranial magnetoelectric encephalopathy treatment instrument (brand name: AOBO Parkinson’s Treatment Instrument) treatmenting parkinson's disease.[Methods] Use methods of double center,randomized, double blind, self crossover, 22 Parkinson’s patients who met the inclusion criteria were randomly divided into A group and B group, then were carried on the curative effect analysis, and were observed therapeutic effect.[Results] The treatment group of 22 cases, basically cured in 0 cases, markedly effective in 9 cases, effective in 8 cases, ineffective in 5 cases. The total efficiency rate and total effective rate were 40.91% (9/22) or 77.27% (17/22) respectively. The control group of 22 cases, basically cured in 0 cases, markedly effective in 2 cases, effective in 3 cases, ineffective in 17 cases. The total efficiency rate and total effective rate were 9.09% (2/22) or 22.73% (5/22) respectively, the total effective rate and total effective rate in the treatment group were higher than those in the control group, the difference was statistically significant (P<0.05). Among them, the main symptoms of resting tremor, rigidity, bradykinesia, evaluation, the treatment group has significant difference (P<0.01); There was no significant difference in the control group (p>0.05); There was significant difference between the treatment group and the control group (p<0.05).[Conclusions] Transcranial magnetoelectric stimulation can significantly improve resting tremor, muscle rigidity, bradykinesia in patients with Parkinson’s disease and other symptoms, and the use of safety. "

Objective] Evaluate on the treatment efficacy and safety for transcranial magnetoelectric encephalopathy treatment instrument (brand name: AOBO Parkinsons Treatment Instrument) treatmenting parkinson's disease.[Methods] Use methods of double center,randomized, double blind, self crossover, 22 Parkinsons patients who met the inclusion criteria were randomly divided into A group and B group, then were carried on the curative effect analysis, and were observed therapeutic effect.[Results] The treatment group of 22 cases, basically cured in 0 cases, markedly effective in 9 cases, effective in 8 cases, ineffective in 5 cases. The total efficiency rate and total effective rate were 40.91% (9/22) or 77.27% (17/22) respectively. The control group of 22 cases, basically cured in 0 cases, markedly effective in 2 cases, effective in 3 cases, ineffective in 17 cases. The total efficiency rate and total effective rate were 9.09% (2/22) or 22.73% (5/22) respectively, the total effective rate and total effective rate in the treatment group were higher than those in the control group, the difference was statistically significant (P<0.05). Among them, the main symptoms of resting tremor, rigidity, bradykinesia, evaluation, the treatment group has significant difference (P<0.01); There was no significant difference in the control group (p>0.05); There was significant difference between the treatment group and the control group (p<0.05).[Conclusions] Transcranial magnetoelectric stimulation can significantly improve resting tremor, muscle rigidity, bradykinesia in patients with Parkinsons disease and other symptoms, and the use of safety. "

10.12074/201901.00071V2

临床医学神经病学、精神病学

ranscranial magnetoelectricParkinson's Treatment InstrumentThe theory of brain cell activationDopamineVoltage-gated Ca2+ channels

ranscranial magnetoelectricParkinson's Treatment InstrumentThe theory of brain cell activationDopamineVoltage-gated Ca2+ channels

.linical study on Transcranial magnetoelectric encephalopathy treatment instrument treatmenting parkinson’s disease[EB/OL].(2019-01-15)[2025-08-02].https://chinaxiv.org/abs/201901.00071.点此复制

评论